• The company’s investigation has shown that a small number of HY vials within several HyQvia batches on the market (refer to batch list in Attachment 1) could potentially be impacted by an inefficient crimping of the aluminum cap of the HY vial present in the dual-vial unit – the defect is not associated with the immunoglobulin vial